Synthesis of Eel-Calcitonin and [Asu1,7]-Eel-Calcitonin: Contribution of the disulfide bond to the hormonal activity

Morikawa, Tadanori; Munekata, Eisuke; Sakakibara, Shumpei; Noda, Toshiharu; Otani, Motoyasu

doi:10.1007/bf01927568

Cited by 92 publications

(35 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The eel calcitonin analogue, elcatonin, was synthesized (Morikawa et al, 1976) and proved to have the same properties of inhibiting bone resorption and lowering the elevated serum calcium level as natural calcitonins.…”

Section: Discussionmentioning

confidence: 99%

Suppressive effect of elcatonin, an eel calcitonin analogue, on excessive urinary hydroxyproline excretion in polyostotic fibrous dysplasia (McCune-Albright's syndrome).

et al. 1983

View full text Add to dashboard Cite

A 12-year-old Japanese girl with polyostotic fibrous dysplasia and endocrine concomitants, was treated with elcatonin, a synthetic eel calcitonin analogue, 10 MRC unit/twice a week given by intramuscular injection.Significant decreases in 24 hr urinary content of hydroxyproline and other amino acids from bone collagen were observed during the course of treatment over 5 months.This biochemical result suggests that the synthetic eel calcitonin analogue exhibits the therapeutic effect in patients with polyostotic fibrous dysplasia by inhibiting bone resorption.

show abstract

Section: Discussionmentioning

confidence: 99%

Suppressive effect of elcatonin, an eel calcitonin analogue, on excessive urinary hydroxyproline excretion in polyostotic fibrous dysplasia (McCune-Albright's syndrome).

et al. 1983

View full text Add to dashboard Cite

show abstract

“…Elcatonin, a synthetic analogue of natural eel calcitonin, has been reported to possess hypocalcemic activity comparable to that of natural eel calcitonin and has been reported to be physicochemically more stable than the natural product (7,8). We have reported that elcatonin markedly inhibits gastric acid secretion (9) and the development of the water-immersion stress-induced ulcers (10) in rats.…”

mentioning

confidence: 99%

“…Solcoseryl (1 and 2 ml/kg/day), secretin (30 and 100 u/kg/day) and cimetidine (30 and 100 mg/kg/day) did not show the inhibitory activity. 7. Acetic acid-induced ulcers in dogs: Ulcers in the control group healed on the 37th day after injection of acetic acid (Table 8).…”

mentioning

confidence: 99%

Effect of elcatonin on experimental gastric and duodenal ulcers.

Ohno¹,

Noguchi²,

Takayanagi³

1985

Jpn.J.Pharmacol

View full text Add to dashboard Cite

Abstract-The antiulcer action of elcatonin, an analogue of natural eel calcitonin , was compared with that of cimetidine, secretin and solcoseryl.Elcatonin (3 to 10 u/kg, s.c.) inhibited the development of gastric ulcers induced by pylorus ligation, water immersion stress, aspirin and reserpine and duodenal ulcers induced by cysteamine in rats. Moreover, once daily injections of elcatonin (1 to 10 u/kg/day, s.c.) promoted the healing of acetic acid-induced chronic gastric ulcers not only in rats but in dogs.The healing effect persisted after the cessation of administrations. Cimetidine (30 to 100 mg/kg, p.o.) inhibited the development of gastric ulcers induced by water-immersion stress , aspirin and reserpine and duodenal ulcers induced by cysteamine in rats. However, once daily administrations of cimetidine (30 to 100 mg/kg/day, p.o.) did not show significant effect on acetic acid-induced chronic gastric ulcers in rats. Secretin (30 to 100 u/kg, s.c.) inhibited the develop ment of gastric ulcers induced by pylorus ligation, water-immersion stress, aspirin and reserpine in rats, but was not effective on cysteamine-induced duodenal ulcers and acetic acid-induced chronic gastric ulcers in rats. Solcoseryl (2 ml/kg, s.c.) inhibited only the development of water-immersion stress-induced gastric ulcers in rats. These results suggest that elcatonin is different from these reference drugs in its properties of action on experimental ulcers. Mechanisms of the antiulcer action of elcatonin which has a superior effect on experimental ulcers are discussed.

show abstract

“…[8][9][10] Both in vivo and in vitro studies have also demonstrated that ECT suppresses bone resorption.…”

mentioning

confidence: 99%

Elcatonin in Combination with Risedronate Is More Effective than Risedronate Alone for Relieving Back Pain in Postmenopausal Women with Osteoporosis

Takakuwa¹,

Iwamoto

2012

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Intramuscularly administered elcatonin (ECT) reduces pain via the central nervous system. A prospective study was performed to determine whether ECT has a beneficial effect on back pain and function in postmenopausal women with osteoporosis during bisphosphonate therapy. Sixty-one postmenopausal osteoporotic women with back pain (mean age: 73.7 years, range: 54-96 years) were divided into two groups: the control group (n 30) and the ECT (intramuscular, 20 units a week) group (n 31). All patients received treatment with risedronate (17.5 mg weekly). The duration of the study was 8 weeks. Urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX), visual analogue scale (VAS) for back pain at rest and movement, and Roland-Morris Disability Questionnaire (RDQ) score for function were assessed. Urinary NTX levels, VAS at rest and movement, and RDQ score markedly decreased during 8 weeks of treatment in both ECT and control groups. A significant reduction in VAS at movement, but not in VAS at rest and RDQ score, was noted in the ECT group than in the control group. This effect was observed from 2 weeks after the start of therapy. These results suggested that ECT in combination with risedronate was more effective than risedronate alone for reducing back pain in postmenopausal women with osteoporosis.Key words elcatonin; risedronate; clinical vertebral fracture; postmenopausal woman; back pain Osteoporosis is commonly observed particularly in postmenopausal women, placing them at a significant risk of a fracture. Risedronate has been widely used as the first-line treatment for postmenopausal osteoporosis, because current evidence, based strictly on the principles of evidence-based medicine (EBM), suggests the efficacy of risedronate to reduce fracture incidence as well as its safety in postmenopausal women with osteoporosis.1-3) A recent systematic review analyzing 7 randomized controlled trials (RCTs) involving 14049 women confirms both clinically important and statistically significant reductions in vertebral, nonvertebral, and hip fractures after secondary prevention therapy. 4) It has been reported that the effect of risedronate to prevent clinical vertebral and nonvertebral fractures is recognized as early as 6 months after the start of treatment in postmenopausal women with osteoporosis.5,6) The anti-resorptive effects of nitrogen-containing bisphosphonates appear to result from their inhibition of an enzyme, farnesyl pyrophosphate synthase (FPPS), in osteoclasts.7) FPPS is a key enzyme in the mevalonate pathway, which generates isoprenoid lipids utilized for post-translational modification of small guanosine 5′-triphosphate (GTP)-binding proteins that are essential for osteoclast function. 7) One possible explanation for the early anti-fracture effect of risedronate is such inhibitory effect on FPPS in osteoclasts.Intramuscular treatment with elcatonin (ECT) is commonly used in Japan. ECT is a derivative of eel calcitonin synthesized by substituting an ethylene bond for its disulfide bond.8) ...

show abstract

Synthesis of Eel-Calcitonin and [Asu1,7]-Eel-Calcitonin: Contribution of the disulfide bond to the hormonal activity

Cited by 92 publications

References 11 publications

Suppressive effect of elcatonin, an eel calcitonin analogue, on excessive urinary hydroxyproline excretion in polyostotic fibrous dysplasia (McCune-Albright's syndrome).

Suppressive effect of elcatonin, an eel calcitonin analogue, on excessive urinary hydroxyproline excretion in polyostotic fibrous dysplasia (McCune-Albright's syndrome).

Effect of elcatonin on experimental gastric and duodenal ulcers.

Elcatonin in Combination with Risedronate Is More Effective than Risedronate Alone for Relieving Back Pain in Postmenopausal Women with Osteoporosis

Contact Info

Product

Resources

About